Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation

Cancer Biology and Therapy

Volumn 15, Issue 10, 2014, Pages 1404-1412

  Zhao, Zhen ^a   Li, Rui ^b   Sha, Sha ^a   Wang, Qiong ^a   Mao, Weidong ^a   Liu, Tao ^a  

^a JIANGYIN PEOPLE S HOSPITAL   (China)

^b First Hospital of Yunnan Province   (China)

Author keywords

Breast cancer; HER3; miRNA 450b 3p

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MICRORNA; MICRORNA 450B 3P; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN HER3; PROTEIN KINASE B; TRASTUZUMAB; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MIRN450 MICRORNA, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; TUMOR MARKER;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OPEN READING FRAME; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

3' UNTRANSLATED REGIONS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; FEMALE; HETEROGRAFTS; HUMANS; MICE, NUDE; MICRORNAS; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, ERBB-3; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84908459438     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.29923     Document Type: Article

References (35)

1. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309: 418-25; PMID: 6328312; http://dx.doi.org/10.1038/309418a0
2. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-12; PMID: 2158859; http://dx.doi.org/10.1016/0092-8674(90)90801-K
3. Shiraishi M, Noguchi M, Shimosato Y, Sekiya T. Amplification of protooncogenes in surgical specimens of human lung carcinomas. Cancer Res 1989; 49: 6474-9; PMID: 2573414
4. Gerosa MA. Talarico D, Fognani C, Raimondi E, Colombatti M, Tridente G, De Carli L, Della Valle G. Overexpression of N-ras oncogene and epidermal growth factor receptor gene in human glioblastomas. J Natl Cancer Inst 1989; 81: 63-7; PMID: 2908920; http://dx.doi.org/10.1093/jnci/81.1.63
5. Cowley GP, Smith JA, Gusterson BA. Increased EGF receptors on human squamous carcinoma cell lines. Br J Cancer 1986; 53: 223-9; PMID: 2420349; http://dx.doi.org/10.1038/bjc.1986.39
6. Rao VH, Kandel A, Lynch D, Pena Z, Marwaha N, Deng C, Watson P, Hansen LA. A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion. Oncogene 2012; 31: 2888-98; PMID: 21986939; http://dx.doi.org/10.1038/onc.2011.460
7. Berger MB, Mendrola JM, Lemmon MA. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 2004; 569: 332-6; PMID: 15225657; http://dx.doi.org/10.1016/j.febslet.2004.06.014
8. Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sánchez V, Koland J, Muller WJ, Arteaga CL, et al. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res 2012; 72: 2672-82; PMID: 22461506; http://dx.doi.org/10.1158/0008-5472.CAN-11-3594
9. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995; 10: 1813-21; PMID: 7538656
10. rd, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994; 14: 3550-8; PMID: 7515147
11. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43; PMID: 17463250; http://dx.doi.org/10.1126/science.1141478
12. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 1994; 13: 2831-41; PMID: 8026468
13. Bezler M, Hengstler JG, Ullrich A. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol Oncol 2012; 6: 516-29; PMID: 22841590; http://dx.doi.org/10.1016/j.molonc.2012.07.001
14. Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A 2012; 109: 2718-23; PMID: 21368164; http://dx.doi.org/10.1073/pnas.1018001108
15. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479-86; PMID: 17110380; http://dx.doi.org/10.1074/jbc.M609383200
16. Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J 2012; 447: 417-25; PMID: 22853430; http://dx.doi.org/10.1042/BJ20120724
17. Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008; 455: 64-71; PMID: 18668037; http://dx.doi.org/10.1038/nature07242
18. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-31; PMID: 15211354; http://dx.doi.org/10.1038/nrg1379
19. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich K P, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68: 5878-87; PMID: 18632642; http://dx.doi.org/10.1158/0008-5472.CAN-08-0380
20. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem 2009; 284: 24696-704; PMID: 19584056; http://dx.doi.org/10.1074/jbc.M109.030098
21. Iorio M V, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, Tagliabue E. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69: 2195-200; PMID: 19276373; http://dx.doi.org/10.1158/0008-5472.CAN-08-2920
22. Delić D, Dkhil M, Al-Quraishy S, Wunderlich F. Hepatic miRNA expression reprogrammed by Plasmodium chabaudi malaria. Parasitol Res 2011; 108: 1111-21; PMID: 21085987; http://dx.doi.org/10.1007/s00436-010-2152-z
23. Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, Radova L, Vyzula R, Slaby O. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol 2012; 7: 195; PMID: 23167930; http://dx.doi.org/10.1186/1748-717X-7-195
24. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, Croce CM. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A 2012; 109: 3024-9; PMID: 22315424; http://dx.doi.org/10.1073/pnas.1200010109
25. Ferracin M, Querzoli P, Calin GA, Negrini M. MicroRNAs: toward the clinic for breast cancer patients. Semin Oncol 2011; 38: 764-75; PMID: 22082762; http://dx.doi.org/10.1053/j.seminoncol.2011.08.005
26. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel MA. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007; 67: 2456-68; PMID: 17363563; http://dx.doi.org/10.1158/0008-5472.CAN-06-2698
27. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 2011; 108: 5021-6; PMID: 21385943; http://dx.doi.org/10.1073/pnas.1016140108
28. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst 2013; 105: 266-73; PMID: 23221996; http://dx.doi.org/10.1093/jnci/djs501
29. Takikita M, Xie R, Chung JY, Cho H, Ylaya K, Hong SM, Moskaluk CA, Hewitt SM. Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med 2011; 9: 126; PMID: 21801427; http://dx.doi.org/10.1186/1479-5876-9-126
30. Trocmé E, Mougiakakos D, Johansson CC, AllEriksson C, Economou MA, Larsson O, Seregard S, Kiessling R, Lin Y. Nuclear HER3 is associated with favorable overall survival in uveal melanoma. Int J Cancer 2012; 130: 1120-7; PMID: 21484789; http://dx.doi.org/10.1002/ijc.26118
31. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI, Ellis IO. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004; 91: 1532-42; PMID: 15480434; http://dx.doi.org/10.1038/sj.bjc.6602184
32. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002; 196: 17-25; PMID: 11748637; http://dx.doi.org/10.1002/path.1003
33. Renart J, Reiser J, Stark GR. Transfer of proteins from gels to diazobenzyloxymethyl-paper and detection with antisera: a method for studying antibody specificity and antigen structure. Proc Natl Acad Sci U S A 1979; 76: 3116-20; PMID: 91164; http://dx.doi.org/10.1073/pnas.76.7.3116
34. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1: 2315-9; PMID: 17406473; http://dx.doi.org/10.1038/nprot.2006.339
35. Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, Zhu MH, Zhang SH. ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res 2011; 17: 710-20; PMID: 21196414; http://dx.doi.org/10.1158/1078-0432.CCR-10-0331